Taken together, these data suggest treatment with AD-8007 can significantly reduce BCBM tumor burden and extend survival in vivo, futher validating our novel ACSS2 inhibitors as possible canidates for the treatment of BCBM patients. The gene discussed is ACSS2; the disease is neoplasm.